Learn about how different healthcare providers work together to help breast cancer patients weigh their treatment options.

Inside UC Health's new Blood Cancer Healing Center, a dedicated team is committed to clinical trials and research that could ...

The FDA has approved Imfinzi® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with MIBC.

The Miami-based company isn't alone in making that bet. Gannon University and Saint Vincent Hospital announced plans Wednesday to develop two new laboratories inside Gannon's Institute for ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

NICE has rejected Pfizer’s Ibrance breast cancer drug in first draft guidance, citing the treatment's high cost. The decision confirms the company’s fears that the drug would fare badly under ...

Brain cancer remains one of medicine’s most formidable challenges, requiring sophisticated treatment approaches tailored to each patient’s specific situation. With advances in surgical ...

Clinical trials test the safety and effectiveness of new cancer drugs and treatments. They help us find better ways to prevent, diagnose, and treat cancer. Nearly all current cancer treatments started ...

Only around one in every 10 treatments was found to be effective in relieving lower back pain, according to a new study published in BMJ Evidence-Based Medicine. staras – stock.adobe.com For ...

Itovebi, combined with Ibrance and Faslodex, is approved for specific advanced breast cancer cases with PIK3CA mutations ... The Itovebi combination regimen was approved in October 2024 for the ...

Targeted treatments like Roche’s trastuzumab (Herceptin) have transformed outcomes for patients with HER2-positive breast cancer. Similarly, Pfizer’s palbociclib (Ibrance), a CDK4/6 inhibitor, has ...